Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Inari Medical Inc Market Cap
From what 6 stock analysts predict, the share price for Inari Medical Inc (NARI) might increase by 40.31% in the next year. This is based on a 12-month average estimation for NARI. Price targets go from $63.00 to $100.00. The majority of stock analysts believe NARI is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 6 Wall Street analysts have assignedNARI 5 buy ratings, 1 hold ratings, and 0 sell ratings. This means that analysts expect Inari Medical Inc to buy. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on NARI. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| richard newitter Truist Financial | Hold | $63.0 | maintained | Jan 30, 2024 |
| michael matson Needham | Buy | $72.0 | initiatedcoverage | Jan 23, 2024 |
| adam maeder Piper Sandler | Buy | $85.0 | rated | Jan 17, 2024 |
| larry biegelsen Wells Fargo | Buy | $100.0 | maintained | Jan 11, 2024 |
| marie thibault BTIG | Buy | $93.0 | maintained | Jan 1, 2024 |
| william plovanic Canaccord Genuity | Buy | $79.0 | maintained | Dec 21, 2023 |
| travis steed Bank of America Securities | Buy | $68.0 | reiterated | Nov 6, 2023 |
| david rescott Robert W. Baird | Buy | $65.0 | reiterated | Nov 2, 2023 |
| ryan zimmerman BTIG | Buy | $93.0 | maintained | Oct 16, 2023 |
| christopher pasquale Nephron | Buy | None | initiatedcoverage | Jul 21, 2023 |
| kallum titchmarsh Morgan Stanley | Buy | $83.0 | initiatedcoverage | May 30, 2023 |
| cecilia furlong Morgan Stanley | Buy | $83.0 | reiterated | Feb 28, 2023 |
| matthew taylor Jefferies | Buy | $91.0 | maintained | Jan 12, 2023 |
| dev weerasuriya Berenberg Bank | Buy | $86.0 | initiatedcoverage | Nov 18, 2022 |
| danielle antalffy SVB Securities | Buy | $110.0 | rated | May 5, 2022 |
| bob hopkins Bank of America Securities | Hold | $105.0 | reiterated | Aug 12, 2021 |
Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy systems for the specific disease states in the United States. The company provides ClotTriever, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; and FlowTriever, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases. It serves interventional radiologists, interventional cardiologists, and vascular surgeons. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.
When did it IPO
2020
Staff Count
1,100
Country
United States
Sector/Industry
Healthcare/Medical Devices
CEO
Mr. Andrew J. Hykes
Market Cap
$3.37B
In 2023, NARI generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that NARI's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2019
Revenue From 2020
Revenue From 2021
Revenue From 2022
LITE-USD
$49.77
NCNO-USD
$29.95
MQ-USD
$6.52
RELY-USD
$18.38
ACIW-USD
$30.56
ALRM-USD
$69.98
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
